UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System
Alcon Research, LLC · Decision date Sep 30, 2026
What did the FDA decide?
FDA recorded an OK30 decision dated 2026-09-30 for P220030/S012, a 30-Day Notice supplement to the approved application for UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, submitted by Alcon Research, LLC. The supplement reason is listed as a process change affecting manufacturer, sterilizer, packager or supplier. The action covers the recorded manufacturing changes only; it is not a new approval of the gas or the delivery system as a whole.
The recorded changes are three: an alternate supplier for UNIFEYE screen and pad printing operations; an alternate third-party supplier of ink and additive for printed components; and an alternate third-party supplier for machining and passivating the Valve Seat component. The device category is gases used within the eye to place pressure on a detached retina, with ophthalmic specialty and product code LPO. The source record includes no documents, so the review basis and any supplier qualification details remain unknown.
FDA approval order statement
Approval of implementing the following manufacturing changes: 1) Alternate supplier for the UNIFEYE screen and pad printing operations; 2) Alternate ink and additive third-party supplier for the UNIFEYE printed components; 3) Alternate third-party supplier to perform the machining and passivating processes for the Valve Seat component.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Sep 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220030/S012
- Regulatory pathway
- PMA supplement
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- Decision code
- OK30
- Decision date
- Sep 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gases used within eye to place pressure on detached retina.
- Applicant
- Alcon Research, LLC
- Product code
- LPO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220030 · Original PMA
UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery System, UNIPURE C3F8 Ophthalmic Gas in the UNIPEXY Gas Delivery
P220030/S012 received
Application receipt date recorded by FDA.
P220030/S012 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P220030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA approval | Jul 2, 2024 | FDA |
Explore the linked device profile
Other records with product code LPO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA approval | Aug 26, 2024 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alcon Research, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 20511 Lake Forest Dr., Lake Forest, CA, 92630
Sources and methodology
- Original FDA record: P220030/S012
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

